[{"id":"5450c8f1-79ea-4dc3-b6b6-f33328de0832","acronym":"","url":"https://clinicaltrials.gov/study/NCT05641493","created_at":"2022-12-07T15:57:22.785Z","updated_at":"2024-07-02T16:35:50.973Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation","source_id_and_acronym":"NCT05641493","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • RX208"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 03/04/2025","primary_completion_date":" 03/04/2025","study_txt":" Completion: 02/27/2026","study_completion_date":" 02/27/2026","last_update_posted":"2023-04-10"},{"id":"77c8d6a3-7ae7-4968-ba8f-4d9cfeb7486a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114603","created_at":"2021-11-10T14:12:49.553Z","updated_at":"2024-07-02T16:36:11.048Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation","source_id_and_acronym":"NCT05114603","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RX208"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2022-05-03"},{"id":"42c3fd75-2fe8-466d-914c-90b48349e704","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065398","created_at":"2021-10-04T13:53:06.541Z","updated_at":"2024-07-02T16:36:18.175Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation","source_id_and_acronym":"NCT05065398","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RX208"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/15/2021","start_date":" 11/15/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-01-21"}]